Combination effect of doxorubicin and HIF inhibitor on MCF-7 CD44+/CD24- subpopulation cells in hypoxic condition

Hypoxia-inducible factors (HIFs) and cancer stem cells (CSCs) are two challenging causes of radiotherapy chemotherapy resistance, leading to most cases failure recurrence in breast therapy. This study was conducted investigated the inhibitory effect combination therapy with doxorubicin (an anthracycline) FM19G11 HIF inhibitor) on MCF-7 their CSC-like (CSC-LCs). CSC-LCs a CD44+/CD24- phenotype were sorted characterized by flow cytometry. A caused more cytotoxic effects compared monotherapy. The largest synergistic observed under hypoxic conditions; however, showed no synergism normoxic conditions. administration induced late apoptotic necrotic cell death CSC-LCs. Additionally, G2 phase arrest both cells. Our results demonstrated that co-administration had hypoxia improved drug resistance